In a first for up­start syn­thet­ic bi­ol­o­gy field, Zymer­gen files for $100M IPO

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Five years af­ter the syn­thet­ic bi­ol­o­gy com­pa­ny Zymer­gen …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER